The ubiquitin proteasome system (UPS) degrades individual proteins in a highly regulated
fashion and is responsible for the degradation of misfolded, damaged, or unneeded cellular …

Deregulation of protein post-translational modifications is intensively involved in the etiology
of diseases, including degenerative diseases, inflammatory injuries, and cancers …

Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival.
Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a …

Background Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to
CD138, which is overexpressed on multiple myeloma (MM) cells. Patients and Methods We …

Proteasome inhibitors have shown relevant clinical activity in several hematological
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …

Although the introduction of bortezomib as a therapeutic strategy has improved the overall
survival of multiple myeloma (MM) patients, 15–20% of high-risk patients do not respond to …

Histone deacetylase (HDAC) inhibitors and proteasome inhibitors have been approved by
the FDA for the treatment of multiple myeloma and lymphoma, respectively, but have not …

Drug resistance is a well-known phenomenon leading to a reduction in the effectiveness of
pharmaceutical treatments. Resistance to chemotherapeutic agents can involve various …

FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other
hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug …

Simple Summary The objective of this study was, firstly, to investigate the relationship
between Histone deacetylase 6 (HDAC6) expression and survival in patients with ovarian …